Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.


Player Avatar Momentum21 (44.78) Submitted: 1/23/2013 3:53:34 PM : Underperform Start Price: $3.86 KERX Score: -132.39

sold in Real Life at 3.82, now flipping short

Report this Post 2 Replies
Member Avatar Momentum21 (44.78) Submitted: 1/28/2013 12:20:18 PM
Recs: 1


Member Avatar Momentum21 (44.78) Submitted: 1/30/2013 9:46:48 AM
Recs: 1

it is OK to miss a run or two, but making a mistake on a short in real life can be deadly. take note!

Featured Broker Partners